An Update on Inhibitors of Human 14 kDa Type II s-PLA2 in Development

Dane M. Springer

doi:10.2174/1381612013398275

Abstract

Recent progress in the development of inhibitors of human Type II s-PLA2 as potential anti-inflammatory agents is presented. While many companies have curtailed their efforts in the PLA2 area, Eli Lilly and Shionogi are continuing to advance LY-315920 (S-5920) as a potential treatment for sepsis and other diseases that have an inflammatory component. The Lilly developmental effort leading to LY-315920 is extensively reviewed, as well as the current status of other small molecular weight inhibitors of Type II s- PLA2 that have been reported to be in late-stage development.

« Previous Next »

Rights & Permissions Print Cite

Current Pharmaceutical Design

Title: An Update on Inhibitors of Human 14 kDa Type II s-PLA2 in Development

Volume: 7 Issue: 3

Author(s): Dane M. Springer

Affiliation:

Abstract: Recent progress in the development of inhibitors of human Type II s-PLA2 as potential anti-inflammatory agents is presented. While many companies have curtailed their efforts in the PLA2 area, Eli Lilly and Shionogi are continuing to advance LY-315920 (S-5920) as a potential treatment for sepsis and other diseases that have an inflammatory component. The Lilly developmental effort leading to LY-315920 is extensively reviewed, as well as the current status of other small molecular weight inhibitors of Type II s- PLA2 that have been reported to be in late-stage development.

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Dane M. Springer , An Update on Inhibitors of Human 14 kDa Type II s-PLA2 in Development, Current Pharmaceutical Design 2001; 7 (3) . https://dx.doi.org/10.2174/1381612013398275